Angiogenesis, the formation of new blood vessels from an existing vasculature, is a complex multistep process involving degradation of extracellular matrix proteins and activation, proliferation and migration of endothelial cells and pericytes (Folkman and Shing, 1992; Diaz-Flores et al, 1994; Folkman, 1995) . It plays a key role in physiological processes involving neovascularization, such as ovulation, placentation and embryogenesis, and is also central to several pathological processes, such as tumour growth and metastasis. Several factors have been identified that have angiogenic activity, but one of the most potent and specific that has both angiogenic and vasculogenic activity is vascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF) and vasculotropin Ferrara et al, 1995; Thomas 1996 ).
An endothelial-specific mitogen with additional activities on endothelial cells, including induction of shape change, protease production and migration Ferrara et al, 1995;  Thomas, 1996) , VEGF is a potent stimulator of angiogenesis in both in vitro and in vivo models and induces microvascular hyperpermeability. Originally identified as a secreted product of tumour cells (Senger et al, 1983 (Senger et al, , 1986 , it is now apparent that VEGF is part of an emerging group of related molecules having approximately 15-25% homology at the amino acid level with the platelet-derived growth factor family. Other recently identified members include VEGF-related factor (VRF) or VEGF-B, VEGFReceived 27 November 1996 Revised 5 August 1997 Accepted 5 August 1997 Correspondence to: RE Banks C (Grimmond et al, 1996; Joukov et al, 1996; Olofsson et al, 1996; Paavonen et al, 1996) and placenta growth factor (Maglione et al, 1991; Hauser and Weich, 1993; Maglione et al, 1993) . The active form of VEGF is a homodimeric cytokine of molecular weight 34-46 kDa, the variation in size being due to alternative exon splicing producing four different isoforms of 121, 165, 189 and 206 amino acids (monomeric size), the last three of which have heparin binding activity (Houck et al, 1991; Tischer et al, 1991) . Many cell types produce VEGF Ferrara et al, 1995; Thomas 1996) , with VEGF165 being the predominant soluble isoform and VEGF189 and VEGF206 remaining almost completely cell-or extracellular matrix-associated unless proteolytically cleaved . Two high-affinity receptors for VEGF have been identified and cloned, namely the fins-like tyrosine kinase Flt-1 and the KDR (kinase insert domain-containing receptor)/Flk-l tyrosine kinase (Shibuya et al, 1990; Matthews et al, 1991; Terman et al, 1991; de Vries et al, 1992; Millauer et al, 1993) . Found predominately on endothelial cells, VEGF receptors have also been found on a limited number of other cell types, including haematopoietic stem cells, megakaryocytes, platelets, monocytes and ovarian tumour cells (Boocock et al, 1995; Katoh et al, 1995; Barleon et al, 1996) .
A key role for VEGF in tumour biology is supported by observations of production by numerous tumour cell lines (Senger et al, 1983 (Senger et al, , 1986 and immunohistochemical demonstration in human carcinomas of several tissues, including breast Anan et al, 1996) , lung (Mattern et al, 1996) , liver , gastrointestinal tract (Brown et al, 1993b; Takahashi et al, 1995; Maeda et al, 1996) , bladder (Brown et al, 1993a , O'Brien et al, 1995 , kidney (Brown et al, 1993a; Sato et al, 1994; Takahashi et al, 1994) and ovary (Boocock et al, 1995 ; Abu-Jawdeh et al, (Toi et al, 1993; Guidi et al, 1994; Toi et al, 1994; Takahashi et al, 1995) and between VEGF expression and prognosis in breast, gastric and bladder cancer (O'Brien et al, 1995) . Use of neutralizing antibodies to VEGF or transfection with antisense VEGF cDNA have been shown to result in inhibition of growth of tumour cell lines in nude mice and inhibition of metastatic spread (Asano et al, 1995; Warren et al, 1995; Claffey et al, 1996; Saleh et al, 1996) . Serum concentrations of VEGF have been examined in patients with a range of cancers, with higher serum levels of VEGF being apparent in some patients (Kondo et al, 1994; Ferrari and Scagliotti, 1996; Takano et al, 1996; Dirix et al, 1997) . While investigating the use of circulating VEGF as a possible prognostic indicator in an ongoing study of patients with breast cancer, we made the preliminary observation of higher concentrations of VEGF in serum samples than in matched plasma, which our initial investigations indicated to be due to release of VEGF from platelets (Banks et al, 1996) . We report here the results of our further investigations, which clearly indicate the presence of VEGF in megakaryocytes and its release from platelets, and make recommendations regarding optimal handling of biological samples for accurate measurement of VEGF. The biological implications of the findings are discussed. 
MATERIALS AND METHODS

Measurement of VEGF
Samples were assayed for VEGF using a commercially available sandwich enzyme-linked immunosorbent assay (ELISA) obtained from R & D Systems Europe (Abingdon, UK), which is specific for VEGF, not detecting related molecules, such as PDGF or placental growth factor. The sensitivity of the assay was 9.0 pg ml-' as quoted by the manufacturer. All samples were assayed in duplicate. After the initial observations of higher levels of VEGF in serum samples compared with matched plasma samples, a preliminary evaluation of the assay was carried out assessing recovery and parallelity using a serum and an EDTA plasma sample from a normal volunteer and an EDTA plasma Table 2 VEGF concentrations in blood samples from eight healthy volunteers prepared as described in Table 1 Sample type and VEGF concentration (pg ml-') Donor (2) Serum (3) Citrated plasma (4) Clotted citrated plasma (5) Clotted citrated blood (8) Thrombin-activated PRP (9) Ca activated PRP
sample from a patient with advanced cancer. Recombinant human VEGF (R & D Systems Europe) was added to the samples (spiked) to produce theoretical increases in VEGF concentration of 135 pg ml-1 and 1300 pg ml', the samples were diluted with assay buffer and analysed for VEGF.
VEGF assay and Western blot analysis of platelet concentrates
Platelets were prepared from a 7-day-old platelet concentrate (prepared from platelet-rich plasma) obtained from the Blood Transfusion Service. The platelet suspension (155 ml, 1.542 x 1012 plts 1-1, 0.28 x 109 WBC 1-l) was centrifuged at 2000 g for 10 min at 200C, the supernatant removed and assayed for VEGF and the platelet pellet washed 2x with Tris buffered saline (50 mm Tris-HCl, 150 mm sodium chloride, pH 7.4; TBS) containing 5 mM glucose and 0.129 M sodium citrate. The platelet pellet was then resuspended in 1 ml of TBS containing 5 mm glucose and an excess of thrombin (320 U) added to ensure maximum release. After activation, the releasate was assayed for VEGF. For Western blotting analysis, supernatant from stored platelets diluted with an equal volume of phosphate-buffered saline (PBS) and containing approximately 100 ng of VEGF as measured by immunoassay was incubated for 1 h at 40C with 1 ml of heparin sepharose (Pharmacia). (0) blood (0) 1:3000. Blots were developed using enhanced chemiluminescence (ECL) reagents (Amersham, UK) with subsequent detection of light emitted using XAR5 film (Kodak). Washing between steps was carried out using TBS-T and all antibodies were diluted in TBS-T containing 1% (w/v) dried skimmed milk. Fifty ng of recombinant human VEGF (Peprotech, London, UK) was electrophoresed as a positive control and molecular sizes of protein bands were determined by parallel electrophoresis of biotinylated molecular weight markers (Biorad, Hemel Hempstead, UK). Nonspecific binding of antibodies was determined by parallel incubation of an identical blot with an irrelevant primary antibody in place of the rabbit anti-VEGF. The anti-VEGF antibody specifically reacts with VEGF and does not detect related molecules, such as PDGF, placental growth factor, VEGF-B or VEGF-C (information supplied by the manufacturer).
Immunocytochemistry
Platelet cytospins and normal bone marrow smears were air dried and fixed in acetone for 5 min. Paraffin-embedded sections of a trephine biopsy from a patient with idiopathic thrombocytopenia purpura were dewaxed in xylene and subsequently rehydrated by passage through alcohols to water. Specimens were then incubated with 20% (v/v) normal goat serum in TBS for 5 min before addition of rabbit anti-VEGF (raised against the first 20 N-terminal amino acids; Santa Cruz Biotechnology) at 2.5 jig ml-' in TBS/0.1% (w/v) human serum albumin/0.1% (w/v) sodium azide. Endogenous avidin-biotin binding sites were blocked using the avidin-biotin blocking kit (Vector Interindividual differences exist with significant increases in VEGF concentration occurring with increasing time before sample handling for clotted samples, and EDTA anticoagulated samples in two people. No significant change with time was seen in heparinized samples and a significant increase was seen in citrated plasma levels in only one individual and then only after 2 h. Using the 1 h time point as a comparison for each individual and examining the effects of anticoagulants relative to the citrate, which should be expected to have minimal effect on platelet activation, three of the four volunteers had significantly higher serum VEGF concentrations (Figure SB, P < 0.01; Figure SC , P < 0.0001; Figure SD , P < 0.001). EDTA and heparinized plasma VEGF concentrations were significantly higher in one volunteer ( Figure  SC , P < 0.0001 and P < 0.001 respectively) although EDTA plasma VEGF concentrations in one further volunteer ( Figure 5A ) were higher than those of the citrate sample but just failed to reach statistical significance because of the relatively high standard deviation of the citrate VEGF sample at this time point in this volunteer (although being significantly higher at 30 min and 1 h).
The initial comparison of glass and plastic citrate and EDTA tubes at 1 h showed no significant difference between glass and plastic tubes for VEGF concentrations in citrated plasma. However, the use of glass EDTA tubes rather than plastic appeared to minimize any increase in VEGF in three of the individuals. When this was investigated further in four more individuals, with VEGF concentrations in EDTA plasma from plastic and glass tubes being compared with VEGF concentrations in citrated plasma using glass tubes (samples processed at 30 min and 1 h post-venepuncture), no difference was seen with regard to time (Figure 6 ). However, using the 1-hour time point for comparison purposes, the use of plastic EDTA tubes resulted in significantly higher VEGF concentrations in all four individuals (P < 0.05 or P < 0.01), whereas the use of glass EDTA tubes produced a result significantly higher than that of citrated plasma in only two of the four individuals.
When the VEGF concentrations of the matched citrate and EDTA plasma samples (glass tubes) from the eight healthy volunteers were examined, together with those from five patients with breast cancer, VEGF concentrations of <9-61 pg ml-' and < 9-149 pg ml-', respectively, were found (mean ± s.d. of 27.0 ± 14.0 and 55.2 ± 39.6 respectively). The differences between the two types of sample was statistically significant (P = 0.004),
British Journal of Cancer (1998) although the magnitude of the difference varied considerably between individuals (from 0 to 88 pg ml-').
DISCUSSSION
Angiogenesis is important in both physiological and pathological processes and the pivotal role of VEGF in angiogenesis and vasculogenesis is clearly illustrated by the abnormality of blood vessel development and embryonic lethality resulting from the loss of even a single VEGF allele (Carmeliet et al, 1996; Ferrara et al, 1996) . The regulation of the release of such a cytokine is obviously critical, and the finding here that platelets carry a readily available store of VEGF has implications for early events in several processes involving platelet-endothelial cell interactions, such as wound healing, atherosclerosis and tumour metastasis. Platelets have been implicated in tumour metastasis after observations of circulating tumour cells forming aggregates with platelets, decreased metastatic spread of tumour cells in thrombocytopenic mice compared with normal animals or after treatments that decrease platelet-tumour cell interactions and additionally the procoagulant activity of many tumours leading to activation of platelets (Blood and Zetter, 1990) . Clearly the relevance of platelet-derived VEGF is dependent on its local release and the number of platelets involved and the overall balance with other platelet-derived angiogenic or anti-angiogenic factors, such as platelet-derived endothelial cell growth factor (thymidine phosphorylase), transforming growth factor-5 (TGF-1), interleukin 1 (IL-1) and platelet activating factor-4 (Harrison and Cramer, 1993) .
The results here clearly show that the elevated levels of VEGF in serum are as a result of its release from platelets during the clotting process. Although initially conceivable that matrix effects of serum and plasma or release of protein-sequestered VEGF by protease release during coagulation could account for such effects, the significant correlations between VEGF concentrations of serum and clotted platelet-rich plasma but not platelet-free plasma and those between the theoretical platelet-derived VEGF of serum and platelet-rich plasma would support a platelet-derived source of VEGF. Although platelet number just failed to reach a statistically significant correlation with serum VEGF concentration, this is probably explained by the interindividual variation in platelet VEGF content as exemplified in Figure 2 . Such a wide interindividual variability in cellular production of cytokines is not unexpected, also being the case, for example, for platelet content of TGF-,B (Jiang et al, 1995) . Using immunoassay and Western blotting, the presence of VEGF in platelets was also confirmed by the detection of VEGF in supernatant from purified platelets after activation or prolonged storage, and its presence in megakaryocytes demonstrated immunocytochemically. These results have implications for sample-handling if accurate VEGF measurements are to be made. The material of choice would be citrated plasma processed within 1 h of venepuncture, although heparinized samples may represent a possible alternative and, although not explored here, the addition of inhibitors of platelet degranulation to the blood collection tubes may also be a consideration. Although similar results were obtained for EDTA plasma and citrated plasma in some cases, marked interindividual differences exist, with significant elevations being seen in some individuals, presumably because of differing degrees of platelet activation by EDTA, which were less marked if glass tubes were used. The reason for higher levels of VEGF in one EDTA sample compared with the corresponding serum sample (Figure 5 ), which would be assumed to contain the maximum level of platelet-derived VEGF after platelet activation, is unclear but may reflect release from other cells (e.g. monocytes) or release from a calcium-dependent sequestration, for example a binding protein. Clearly serum is totally unsuitable, with results having the potential to be markedly influenced by platelet number and VEGF content. To date, only a small number of studies have been carried out measuring circulating VEGF concentrations and all have used serum samples (Kondo et al, 1994; Baker et al, 1995; Hanatani et al, 1995; Ferrari and Scagliotti, 1996; Takano et al, 1996; Watanabe et al, 1996; Dirix et al, 1997; Lyall et al, 1997) . Additional factors to be considered when measuring VEGF in clinical samples should include the specificity of the antibodies used in the assay and the possible presence and effect of binding of VEGF to heparin-like molecules, soluble receptors (Kendall and Thomas, 1993; Boocock et al, 1995) and a2-macroglobulin (Soker et al, 1993) .
The question of release of VEGF from platelet concentrates during storage and its biological significance should be addressed. Clearly, in the platelet concentrate sample examined here, significant amounts of VEGF were present in the fluid phase after 7 days storage. However, whether such release of VEGF occurs within the normal shelf-life of such concentrates and whether it is biologically active remains to be determined. Contaminating cytokines, such as TNF-a, IL-1, IL-8 and IL-6, have been described in platelet concentrates prepared from platelet-rich plasma and implicated in transfusion reactions (Muylle et al, 1993; Stack and Snyder, 1994 ) although thought to be derived from contaminating white blood cells, such as monocytes, and significantly reduced when prefiltered (Muylle and Peetermans, 1994; Aye et al, 1995) . A reduction in adverse reactions was also seen when platelet concentrates derived from buffy coats were used (Oksanen et al, 1994) , and studies have reported that white cell contamination in such preparations is low and cytokine contamination is rare (Flegel et al, 1995; Kluter et al, 1995) .
Using immunohistochemical techniques, VEGF appears to be present in megakaryocytes, with labelling being granular in appearance. The inability to detect VEGF in platelets by light microscopy was to be expected, given that the theoretical plateletderived VEGF amounts to approximately five molecules per cell. The immunocytochemical demonstration of VEGF in megakaryocytes would not in itself be conclusive proof of synthesis by these cells as endocytic pathways for proteins, such as albumin and IgG, have been demonstrated (Harrison and Cramer, 1993) . However, while this study was in progress, a recent report has described the presence of mRNA for VEGF in platelets and megakaryocytes (Katoh et al, 1995) . Ultrastructural and release studies are needed to demonstrate whether the VEGF released by platelets Iis contained within cytoplasmic granules or is localized to the membranes, as is the case for IL-I (Hawrylowicz et al, 1989) .
The presence of mRNA for VEGF has also been described in T lymphocytes (Freeman et al, 1995) , CD34+ cells and monocytes (Katoh et al, 1995) , with mRNA for the KDR and Flt-1 genes encoding VEGF receptors also present in CD34+ cells, megakaryocytes and platelets (Katoh et al, 1995) . These results support the immunohistochemical demonstration here of VEGF protein within several cell types of the bone marrow. The role of VEGF within the bone marrow is not clear, but the simultaneous presence of VEGF and its receptors on several haematopoietic cell types may indicate an autocrine or paracrine function in regulating growth or differentiation of these cells, in addition to the regulation of marrow endothelial cells. In further support of this, VEGF was found to enhance colony formation by mature subsets of granulocyte-macrophage and erythroid progenitor cells stimulated with a colony-stimulating factor but inhibited colony formation by more immature subsets of progenitors. In single-cell assays, these effects were absent or reduced implying both direct and indirect actions of VEGF (Broxmeyer et al, 1995) . VEGF also markedly suppressed apoptotic cell death of normal human haematopoietic stem cells or leukaemic cell lines after gamma-ray irradiation (Katoh et al, 1995) , supporting a potential role in survival and maintenance of these cells.
Our observations suggest additional possible mechanisms for the role of VEGF in cancer biology and prognosis. The adherence of circulating tumour cells to platelets may result in platelet activation and release of VEGF. This may result in increased endothelial permeability, allowing cellular extravasation, and local release of VEGF may stimulate neovascularization.
